1. INTRODUCTION
===============

Chemotherapy produces similar survival gains whether given in the neoadjuvant or the adjuvant setting. A meta-analysis of randomized trials comparing neoadjuvant with adjuvant chemotherapy found no difference in distant disease recurrence \[risk ratio ([rr]{.smallcaps}): 0.94; 95% confidence interval ([ci]{.smallcaps}): 0.83 to 1.06\] or overall survival rate ([rr]{.smallcaps}: 1.00; 95% [ci]{.smallcaps}: 0.90 to 1.12) [@b1-co16-5-48]. Notably, however, most of the patients in the relevant trials had operable cancer at randomization.

In the clinical setting, neoadjuvant therapy has several potential advantages over standard adjuvant therapy. First, for operable tumours, the use of neoadjuvant therapy increases the rate of breast-conserving surgery [@b2-co16-5-48],[@b3-co16-5-48], with the caveat that neoadjuvant therapy is associated with an increase in locoregional recurrence ([rr]{.smallcaps}: 1.22; 95% [ci]{.smallcaps}: 1.04 to 1.43), especially in younger women (in whom tamoxifen was not given at the time that the trial was conducted) and in women for whom a mastectomy was initially proposed but was changed to breast-conserving surgery after neoadjuvant chemotherapy [@b2-co16-5-48]. Second, given that a pathologic complete response (p[cr]{.smallcaps}) is a surrogate marker for improved clinical outcome [@b2-co16-5-48], neoadjuvant therapy provides an opportunity to undertake correlative research by allowing *in vivo* assessment of tumour response to particular drug regimens [@b3-co16-5-48]. Lastly, from a practical viewpoint, neoadjuvant therapy allows patients to start treatment earlier if surgical wait times are too long. Neoadjuvant therapy also has its disadvantages, however. First, there is about a 5% chance that tumour progression may occur during neoadjuvant treatment, thereby delaying definitive local therapy [@b4-co16-5-48]. In addition, neoadjuvant treatment prevents definitive pathologic staging.

Locally advanced breast cancer ([labc]{.smallcaps}) and inflammatory breast cancer ([ibc]{.smallcaps}) are, by definition, inoperable, and neoadjuvant therapy is therefore the sole treatment option. Chia *et al.* [@b5-co16-5-48] and Anderson *et al.* [@b6-co16-5-48] both described [labc]{.smallcaps} as stage [iii]{.smallcaps} disease (excluding T4d tumours), with a heterogeneous clinical phenotype that ranges from neglected low-grade estrogen receptor ([er]{.smallcaps})--positive to rapidly progressing [er]{.smallcaps}-negative breast cancer. On the other hand, [ibc]{.smallcaps} (T4d) appears to have a different epidemiology, is typically diagnosed at a younger age, and is generally associated with higher tumour grade, negative [er]{.smallcaps} status, and increased angiogenesis and lymphangiogenesis; historically, [ibc]{.smallcaps} has a worse survival rate [@b5-co16-5-48]--[@b8-co16-5-48].

The human epidermal growth factor receptor 2 ([her]{.smallcaps}2) is a transmembrane tyrosine kinase receptor protein that is part of the [her]{.smallcaps} family of growth factor receptors ([her]{.smallcaps}1--[her]{.smallcaps}4). The [her]{.smallcaps}2 receptor is involved in cell--cell and cell--stroma communication primarily through signal transduction involving the Ras/mitogen-activated protein kinase pathway and the phosphoinositide 3 kinase ([pi]{.smallcaps}3[k]{.smallcaps})/Akt pathway [@b9-co16-5-48]. These signals ultimately promote cell proliferation, survival, and motility. Amplification of the [her]{.smallcaps}2/*neu* gene and resulting overexpression of the [her]{.smallcaps}2 protein occurs in approximately 15%--20% of invasive primary breast cancers [@b10-co16-5-48],[@b11-co16-5-48]. Compared with [her]{.smallcaps}2-negative cancers, early-stage breast cancer with a [her]{.smallcaps}2 alteration is associated with more aggressive disease and a higher risk of relapse [@b12-co16-5-48]--[@b16-co16-5-48].

Trastuzumab is a monoclonal antibody that binds to the extracellular domain of [her]{.smallcaps}2. Several mechanisms of action underlie the antitumour effects of trastuzumab. Trastuzumab blocks [her]{.smallcaps}2- activated cell signalling, thereby reducing cell proliferation and restoring a capacity for apoptosis by inhibiting the [pi]{.smallcaps}3[k]{.smallcaps}/Akt pathway [@b17-co16-5-48]--[@b19-co16-5-48], which increases cellular sensitivity to chemotherapy and radiotherapy [@b20-co16-5-48]. Trastuzumab has been shown to inhibit [her]{.smallcaps}2-regulated angiogenesis [@b17-co16-5-48],[@b21-co16-5-48]--[@b23-co16-5-48] and, in preclinical models, to recruit the immune system through antibody-dependent cellular cytotoxicity, triggering activation of natural killer cell--mediated apoptosis [@b24-co16-5-48]--[@b26-co16-5-48]. Trastuzumab has also been shown to prevent the formation of p95^her^[@b2-co16-5-48] (a truncated, active form of [her]{.smallcaps}2), which may lead to inhibition of tumour development [@b17-co16-5-48],[@b27-co16-5-48].

Trastuzumab is now the standard of care in the adjuvant setting. A meta-analysis [@b28-co16-5-48] of the five randomized controlled trials in the adjuvant setting \[North Central Cancer Treatment Group ([ncctg]{.smallcaps}) 9831, National Surgical Adjuvant Breast and Bowel Project ([nsabp]{.smallcaps}) B31, the Herceptin[a](#fn1-co16-5-48){ref-type="fn"} Adjuvant ([hera]{.smallcaps}) trial, the Finland Herceptin (FinHer) trial, and Breast Cancer International Research Group 006\] [@b29-co16-5-48]--[@b32-co16-5-48] comparing chemotherapy plus trastuzumab with chemotherapy alone in [her]{.smallcaps}2-positive disease observed a relative reduction in relapse of 47% (absolute reduction: 7.1%) and a relative reduction in mortality rate of 48% (absolute reduction: 2.5%) after a follow-up of 2--3 years.

The body of studies evaluating the use of [her]{.smallcaps}2- targeted agents in neoadjuvant therapy for both primary operable and primary inoperable [her]{.smallcaps}2- positive breast cancer is growing, and the present paper reviews the current evidence and outlines suggestions from a panel of Canadian oncologists about the neoadjuvant use of trastuzumab and other [her]{.smallcaps}2-targeted agents.

2. DEVELOPMENT OF PANEL SUGGESTIONS
===================================

The authors of this paper met in Toronto for a 1-day conference in June 2008. The panel reviewed the results of the latest trials using trastuzumab and other [her]{.smallcaps}2-targeted agents in the neoadjuvant, adjuvant, and metastatic disease settings. Based on trial information, suggestions for each setting were formulated. For neoadjuvant therapy, a draft manuscript reviewing the currently available data and outlining the suggestions from the panel was initially written by a medical writer (BW) and reviewed and revised by four panel members (JLe, MC, LP, SC). The final manuscript was reviewed and approved by the rest of the panel members (SD, JLa, JM, KIP, DR, ShV, SuV). Recent clinical trial results (available as of June 2009) were incorporated into the present document, and the conclusions discussed were updated as additional evidence became available.

Development of the Canadian advisory panel and the present manuscript were funded by an unrestricted educational grant from Hoffmann--La Roche Canada. The authors received an honorarium for attending the conference, but not for writing the manuscript. The authors are responsible for the content of the manuscript, with no restrictions set by the sponsor.

The panel focussed on

-   the use of trastuzumab and other [her]{.smallcaps}2-targeted agents as neoadjuvant therapy in primary operable, locally advanced, and inflammatory breast cancer; and

-   possible choices of chemotherapeutic regimens with trastuzumab.

The related clinical evidence is presented and discussed below. Key panel suggestions are followed by a discussion of the supporting evidence, the panel's rationale for the suggestions, and any points on which consensus was lacking.

3. NEOADJUVANT TRIALS USING TRASTUZUMAB
=======================================

Two recently reported randomized controlled prospective trials comparing chemotherapy with and without [her]{.smallcaps}2-targeted therapy in the neoadjuvant setting ([Table I](#tI-co16-5-48){ref-type="table"}) are reviewed here.

3.1 MD Anderson Trial
---------------------

In a small, two-arm, phase [iii]{.smallcaps} randomized prospective trial, Buzdar *et al.* compared 225 mg/m^2^ paclitaxel in a 24-hour continuous intravenous infusion every 3 weeks for 4 cycles, followed by [fec]{.smallcaps} \[500 mg/m^2^ 5-fluorouracil (5[fu]{.smallcaps}) on days 1 and 4, 75 mg/m^2^ epirubicin on day 1, 500 mg/m^2^ cyclophosphamide on day 1\] every 3 weeks for 4 cycles as neoadjuvant therapy without ([p]{.smallcaps}→[fec]{.smallcaps}) and with \[[h]{.smallcaps}+([p]{.smallcaps}→[fec]{.smallcaps})\] concurrent trastuzumab (4 mg/kg loading dose on day 1 of the first treatment cycle before paclitaxel, and 2 mg/kg maintenance dose weekly for 24 doses) [@b3-co16-5-48]. The study accrued 42 patients with histologically confirmed invasive, but noninflammatory, stage [ii]{.smallcaps}--[iiia]{.smallcaps} carcinoma of the breast. The primary objective was to demonstrate a doubled improvement in p[cr]{.smallcaps}---defined as no evidence of residual invasive cancer in both breast and axilla---with the addition of trastuzumab to chemotherapy. The trastuzumab-based treatment arm displayed a p[cr]{.smallcaps} improvement by a factor of 2.5 relative to chemotherapy alone (65.2% vs. 26.3%, *p* = 0.016). As a result of the superior response attributed to trastuzumab, the data analysis was presented to the MD Anderson Data Monitoring Committee. Based on recommendations by that committee, the protocol of the original study was changed to discontinue the chemotherapy-alone arm. Recruitment was continued in the [h]{.smallcaps}+([p]{.smallcaps}→[fec]{.smallcaps}) arm only. A total of 45 patients received the [h]{.smallcaps}+([p]{.smallcaps}→[fec]{.smallcaps}) regimen. The p[cr]{.smallcaps} rate for the updated combined trastuzumab treatment arm (*n* = 45) was also superior to chemotherapy alone (60% vs. 26.3%; 95% [ci]{.smallcaps}: 44.3% to 74.3%; [Table I](#tI-co16-5-48){ref-type="table"}) [@b33-co16-5-48]. Notably, trastuzumab was given concomitantly with epirubicin. The median left ventricular ejection fraction ([lvef]{.smallcaps}) was 65% at baseline in the both trial arms; after 6 months, the median [lvef]{.smallcaps} was 65% (range: 55%--70%) in the ([p]{.smallcaps}→[fec]{.smallcaps}) arm, but 60% (range: 52%--70%) in the [h]{.smallcaps}+([p]{.smallcaps}→[fec]{.smallcaps}) arm. No clinical cardiac dysfunction was reported; however, the sample size was small, and the follow-up duration was short.

3.2 Neoadjuvant Herceptin Trial
-------------------------------

The international multicentre phase [iii]{.smallcaps} randomized [noah]{.smallcaps} (Neoadjuvant Herceptin) trial compared the efficacy of doxorubicin (60 mg/m^2^) and paclitaxel (150 mg/m^2^) every 3 weeks for 3 cycles, followed by paclitaxel alone (175 mg/m^2^) every 3 weeks for 4 cycles, followed by cyclophosphamide (600 mg/m^2^), methotrexate (40 mg/m^2^), and 5[fu]{.smallcaps} (600 mg/m^2^) every 4 weeks on days 1 and 8 for 4 cycles without ([ap]{.smallcaps}→[p]{.smallcaps}→[cmf]{.smallcaps}) and with \[[h]{.smallcaps}+([ap]{.smallcaps}→[p]{.smallcaps}→[cmf]{.smallcaps})\] concurrent trastuzumab \[8 mg/kg loading dose, then 6 mg/kg every 3 weeks (concurrent with cycle 1 onward) continued to 52 weeks\] as first-line therapy in patients with [her]{.smallcaps}2-overexpressing [labc]{.smallcaps} (including [ibc]{.smallcaps}) [@b34-co16-5-48]. A [her]{.smallcaps}2-negative third arm was also accrued as reference for the [her]{.smallcaps}2-overexpressing arms, but these patients were not given trastuzumab. Data presented here refer to the group of [her]{.smallcaps}2-positive patients (trastuzumab arm vs. no trastuzumab arm).

The primary endpoint was event-free survival ([efs]{.smallcaps}), which was defined as progression on therapy, relapse after surgery, or death from any cause. The secondary endpoints were p[cr]{.smallcaps} rate, overall survival, and safety and tolerability. In both [her]{.smallcaps}2-positive arms (with and without trastuzumab), 42%--43% of the patients presented with T4 noninflammatory breast cancer, 27% presented with [ibc]{.smallcaps}, and 30%--31% presented with N2 disease. In the intention-to-treat population (*n* = 227), patients receiving trastuzumab (*n* = 115) experienced a significantly improved 3-year [efs]{.smallcaps} rate relative to chemotherapy alone \[70.1% vs. 53.3%; hazard ratio ([hr]{.smallcaps}): 0.56; 95% [ci]{.smallcaps}: 0.36 to 0.85; *p* = 0.006; [Table I](#tI-co16-5-48){ref-type="table"}\].

In addition, the p[cr]{.smallcaps} rate was significantly higher in the trastuzumab-containing treatment arm (43% vs. 23%, *p* = 0.002), and a trend toward improved overall survival was observed ([hr]{.smallcaps}: 0.65; 95% [ci]{.smallcaps}: 0.34 to 1.23; *p* = 0.18) [@b34-co16-5-48]. The rate of breast-conserving surgery nearly doubled in the trastuzumab arm (23% vs. 12.5%, *p* = 0.07) [@b36-co16-5-48]. In the subgroup of patients with [her]{.smallcaps}2-positive [ibc]{.smallcaps} (*n* = 61), the addition of trastuzumab to chemotherapy also significantly improved p[cr]{.smallcaps} (55% vs. 19%, *p* = 0.004) and total p[cr]{.smallcaps} (48% vs. 13%, *p* = 0.002) [@b35-co16-5-48].

Neoadjuvant trastuzumab was well tolerated with reasonable cardiac safety. Only a 2.1% cumulative incidence of New York Heart Association ([nyha]{.smallcaps}) grade 3 congestive heart failure ([chf]{.smallcaps}) was observed in the trastuzumab arm [@b34-co16-5-48] even though trastuzumab was delivered concurrently with doxorubicin (60 mg/m^2^) and paclitaxel (150 mg/m^2^). In contrast, the non-trastuzumab-containing group in [her]{.smallcaps}2-positive patients and the [her]{.smallcaps}2-negative group both reported no incidence of [nyha]{.smallcaps} grade 3 [chf]{.smallcaps}.

Although this study is very interesting, to date it has been published only in abstract form. No other randomized trials have compared trastuzumab with no trastuzumab treatment. However, a number of other ongoing trials have included trastuzumab as part of the treatment arm in the [her]{.smallcaps}2-overexpressing cohort.

The two trials presented next included concomitant (GeparQuattro) or sequential ([techno]{.smallcaps}) anthracyclines and trastuzumab.

3.3 GeparQuattro Trial
----------------------

A multicentre prospective randomized three-arm trial studied the possible benefits of adding capecitabine, either concomitantly or sequentially, to docetaxel after 4 cycles of epirubicin (90 mg/m^2^) and cyclophosphamide (600 mg/m^2^) [@b37-co16-5-48] ([ec]{.smallcaps}). Patients with [her]{.smallcaps}2-positive breast cancer received trastuzumab for 1 year, starting with [ec]{.smallcaps} in all three arms, thereby collecting data on the cardiac safety of trastuzumab and anthracyclines given concomitantly. Results presented in an abstract form showed only that neoadjuvant trastuzumab was well tolerated, with no cases of grade 4 congestive heart failure. No patients showed a decrease in [lvef]{.smallcaps} to below 45%. The p[cr]{.smallcaps} rate in a combined analysis of all three [her]{.smallcaps}2-positive treatment arms treated with concurrent trastuzumab was 45%. Investigators concluded that the addition of trastuzumab to chemotherapy was feasible without clinically relevant cardiotoxicity.

3.4 Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant Trial
-----------------------------------------------------------------

The multicentre phase [ii]{.smallcaps} single-arm Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant ([techno]{.smallcaps}) trial (NCT00795899) examined the safety and efficacy of epirubicin (90 mg/m^2^) and cyclophosphamide (600 mg/m^2^) every 3 weeks for 4 cycles, followed by trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg) and paclitaxel (175 mg/m^2^) every 3 weeks for 4 cycles as neoadjuvant therapy in patients with [her]{.smallcaps}2-positive primary breast cancer \>2 cm or inflammatory disease [@b38-co16-5-48]. After surgery, patients continued trastuzumab (6 mg/kg) every 3 weeks for 12 cycles. The primary clinical endpoints were histopathologic response rates (breast and axilla) and overall cardiac toxicity; secondary endpoints were disease-free survival, overall survival, rate of breast conservation, and quality of life. This trial has been completed. In an abstract presented in 2006, the p[cr]{.smallcaps} rate was 20% [@b39-co16-5-48].

4. NEOADJUVANT TRIALS USING LAPATINIB
=====================================

Recently, Migliaccio *et al.* [@b19-co16-5-48] performed two sequential single-arm neoadjuvant clinical trials in [her]{.smallcaps}2- overexpresing [labc]{.smallcaps} patients to compare the clinical efficacy and mechanism of action of trastuzumab with those of lapatinib, an oral epidermal growth factor receptor/[her]{.smallcaps}2 tyrosine kinase inhibitor. Patients in the single-arm trastuzumab trial were given a standard trastuzumab dose for the first 3 weeks followed by trastuzumab and standard docetaxel every 3 weeks for 12 weeks (*n* = 35). Patients in the lapatinib single-arm trial were given 1500 mg oral lapatinib daily for 6 weeks followed by trastuzumab and standard docetaxel every 3 weeks for 12 weeks (*n* = 49). Clinical efficacy of the trial that gave initial trastuzumab, as determined by the p[cr]{.smallcaps} rate \[defined here as the complete disappearance of all invasive cancer or minute foci of residual disease (\<0.5 cm) in breast\], was 34% (11/32) as compared with 68% (23/34) in the trial that gave initial lapatinib. It must be noted that, because both trials used trastuzumab with docetaxel, the lapatinib trial was not a lapatinib-only design. Further study results showed that tumours with low [pten]{.smallcaps} predicted resistance to trastuzumab.

5. FUTURE STUDIES
=================

Using [www.clinicaltrials.gov](www.clinicaltrials.gov), we found 14 randomized clinical trials for [her]{.smallcaps}2-positive breast cancer in the neoadjuvant setting ([Table II](#tII-co16-5-48){ref-type="table"}). Most of these trials used p[cr]{.smallcaps} as the primary endpoint.

Eight trials compared trastuzumab with lapatinib or a combination of both agents. One trial (NeoSphere) is currently examining the safety and efficacy of the various combinations of trastuzumab and pertuzumab, another monoclonal antibody that targets [her]{.smallcaps}2, in the presence or absence of chemotherapy for [labc]{.smallcaps} or [ibc]{.smallcaps}. As a complement to trastuzumab, pertuzumab inhibits the [her]{.smallcaps}2-mediated signalling pathway by binding to a different epitope on the [her]{.smallcaps}2 extracellular domain, thereby preventing [her]{.smallcaps}2 dimerization with other members of the [her]{.smallcaps}2 family [@b40-co16-5-48]. *In vitro* evidence suggests that these two agents act synergistically to inhibit the survival of breast cancer cells [@b41-co16-5-48], suggesting that the combination of these two agents would be a more effective therapeutic strategy.

The American College of Surgeons Oncology Group ([acosog]{.smallcaps}) Z1041 trial is examining the sequence of [fec]{.smallcaps}~75~--paclitaxel plus trastuzumab, in which [fec]{.smallcaps}~75~ is given either before or after the paclitaxel and trastuzumab. Other trials are testing new agents such as everolimus.

The German Breast Group 44 trial (GeparQuinto) will randomize 2547 patients to six arms: one without neoadjuvant targeted therapy, one with bevacizumab, one with only trastuzumab and no chemotherapy, one with everolimus, one with chemotherapy plus trastuzumab, and one with chemotherapy plus lapatinib. These large clinical trials may answer many clinical questions, such as "Is it better to give a combination of targeted agents rather than one agent?"

6. PANEL SUGGESTIONS FOR TREATMENT IN NEOADJUVANT THERAPY
=========================================================

6.1 HER2-Targeted Agents as Neoadjuvant Therapy in HER2-Positive Primary Operable LABC or IBC
---------------------------------------------------------------------------------------------

### Suggestion

Currently, the panel felt that trastuzumab is standard in the neoadjuvant setting in combination with chemotherapy in patients with [her]{.smallcaps}2-overexpressing breast cancer when a clinical decision has been made to treat with neoadjuvant chemotherapy. Other [her]{.smallcaps}2-targeting agents such as lapatinib and pertuzumab should be given only as part of a clinical trial.

### Discussion

The addition of trastuzumab in neoadjuvant systemic therapy clearly increases p[cr]{.smallcaps} in primary operable breast cancer, and a growing body of clinical evidence shows a similar result in [labc]{.smallcaps} and [ibc]{.smallcaps}[@b3-co16-5-48],[@b33-co16-5-48]--[@b35-co16-5-48],[@b37-co16-5-48]. Furthermore, increased p[cr]{.smallcaps} after preoperative therapy has been shown to be a surrogate marker for long-term disease-free survival and overall survival in some trials [@b2-co16-5-48],[@b3-co16-5-48]. However, in the [nsabp]{.smallcaps} B27 trial, despite increased p[cr]{.smallcaps}, no survival advantage was shown with the addition of docetaxel to an anthracycline-based regimen. Investigation of new agents in combination with conventional systemic therapies in the preoperative or neoadjuvant setting can provide tissue sampling to assess markers of *in vivo* tumour responses. As well, p[cr]{.smallcaps} can be used as a surrogate, allowing for testing of new interventions in smaller phase [ii]{.smallcaps} trials before they are studied in larger phase [iii]{.smallcaps} clinical trials, which require a larger sample size and longer follow-up.

The latest and strongest evidence relies on the final study results of the [noah]{.smallcaps} trial. Here, the addition of trastuzumab to chemotherapy in [her]{.smallcaps}2-positive patients significantly improved event-free survival at 3 years relative to chemotherapy alone (70.1% vs. 53.3%; [hr]{.smallcaps}: 0.56; 95% [ci]{.smallcaps}: 0.36 to 0.85; *p* = 0.006), with an overall survival trend ([hr]{.smallcaps}: 0.65; 95% [ci]{.smallcaps}: 0.34 to 1.23; *p* = 0.18) [@b34-co16-5-48]. The [hr]{.smallcaps} and absolute benefit for the addition of trastuzumab are in the range seen during the large adjuvant trials with trastuzumab; however, these results were delivered with a much smaller number of patients (*n* = 227 vs. *n* \> 13,000). The acceptable cardiac safety data also show that it may be reasonable to use a low cumulative dose of anthracycline concurrently with trastuzumab. Altogether, the [noah]{.smallcaps} trial has demonstrated that neoadjuvant trastuzumab for 1 year in combination with chemotherapy is a standard of care for women with [labc]{.smallcaps} or [ibc her]{.smallcaps}2-positive breast cancer. Publication of final results is eagerly awaited.

No trial has tested, or is testing, the effect of starting trastuzumab in the neoadjuvant setting against starting it after surgery. The [ncctg]{.smallcaps} 9831 trial has examined the benefits of trastuzumab concurrent with chemotherapy versus trastuzumab sequential after chemotherapy. Results of the data analysis are pending. In regard to duration, based on the adjuvant trials, total duration is 1 year at present. Studies to determine if a 6-month treatment is equivalent to a 12-month treatment (NCT00712140, NCT00615602) or if 2 years' treatment provides further benefits over 1 year's treatment ([hera]{.smallcaps}) are ongoing. In Finland, a trial is also comparing 9 weeks with 51 weeks of adjuvant trastuzumab (NCT00593697).

6.2 Possible Combination Regimens with Trastuzumab
--------------------------------------------------

### Suggestion

Currently, the panel felt that concurrent trastuzumab with the taxane component of commonly-used neoadjuvant regimens is a reasonable standard in primary operable, locally advanced, or inflammatory breast cancer. However, current data are not strong enough to support the concurrent use of trastuzumab with anthracyclines, given the potential cardiac toxicity.

### Discussion

The panel noted that no randomized trials were available in [labc]{.smallcaps} or [ibc]{.smallcaps} to support any particular trastuzumab-based regimen. Several published regimens included concurrent anthracyclines with trastuzumab [@b3-co16-5-48],[@b33-co16-5-48],[@b34-co16-5-48],[@b36-co16-5-48], but caution is needed in using this approach because the overall sample size in these studies is small, the patient populations were highly selected, and the primary aim was not the cardiac safety of trastuzumab treatment given concurrently with anthracyclines. Also, the follow-up for cardiotoxicity was only short-term. It must be noted that the total dose of anthracyclines was lower than that usually given in the adjuvant setting, and the risk-- benefit ratio of these regimens is not fully defined. Long-term follow-up and randomized comparisons of the regimens will be required for definitive recommendations. In the [hera]{.smallcaps} trial, higher cumulative doses of anthracyclines were found to contribute as a risk factor for trastuzumab-associated cardiotoxicity [@b42-co16-5-48]. Although the population benefiting from anthracyclines is that with *TOPO2A* gene alterations, found mainly in [her]{.smallcaps}2-positive breast cancers [@b43-co16-5-48], no evidence supports concurrent anthracycline and trastuzumab in the adjuvant setting. In the metastatic setting, anthracyclines given concurrently have been shown to be associated with an unacceptable rate of cardiac toxicity, and therefore the combination is contraindicated in that setting [@b44-co16-5-48].

In the context of primary operable breast cancer, in which patients seek a better chance for breast conservation, the panel agreed that all adjuvant data could be extrapolated to neoadjuvant therapy for clinical benefit, but with a higher chance of breast conservation. In the context of [labc]{.smallcaps} and [ibc]{.smallcaps}, there is increasing evidence that [her]{.smallcaps}2-targeted strategies used in the adjuvant setting may be applicable in the neoadjuvant setting. Data from the two randomized controlled trials of trastuzumab versus no trastuzumab in operable breast cancer (MD Anderson Trial) or in [labc]{.smallcaps} and [ibc]{.smallcaps} ([noah]{.smallcaps} trial) showed that trastuzumab is associated with a significant increase in p[cr]{.smallcaps}. In the absence of data from randomized trials comparing neoadjuvant with adjuvant trastuzumab, the panel felt that initiating trastuzumab preoperatively and continuing it postoperatively for 1 year in total is reasonable. In an ongoing phase [iii]{.smallcaps} trial in [her]{.smallcaps}2-positive breast cancer (Neo-Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation), the total duration of [her]{.smallcaps}2-targeted therapy is also 1 year.

Whether trastuzumab should be given concurrently with chemotherapy or after chemotherapy remains an open question. Answers will be obtained with the analysis of the [ncctg]{.smallcaps} 9831 trial in which trastuzumab was given concurrently with paclitaxel in one arm and trastuzumab was given sequentially in another arm in the adjuvant setting.

The transfer to the neoadjuvant setting of regimens proven efficacious in the adjuvant setting is supported by a meta-analysis [@b1-co16-5-48]. Although the regimens used were mainly doxorubicin and cyclophosphamide ([ac]{.smallcaps}), [fac]{.smallcaps}, and [fe]{.smallcaps}~60~[c]{.smallcaps}, it is reasonable to believe that other chemotherapy regimens would be as efficacious if given preoperatively compared with postoperatively. However, the optimal duration of chemotherapy is unknown. For example, the preliminary results of the [nsabp]{.smallcaps} 30 trial in operable breast cancer showed that 8 cycles of chemotherapy ([ac]{.smallcaps} followed by docetaxel) were superior to 4 cycles of doxorubicin and docetaxel or of docetaxel, doxorubicin, and cyclophosphamide [@b45-co16-5-48].

Although the efficacy results are quite convincing, the panel warned that a decision to give concurrent neoadjuvant anthracyclines with trastuzumab could not be made based on the neoadjuvant trials conducted to date. More studies and longer follow-up from the aforementioned trials, with particular attention to cardiac effects, are required to provide further insight into the cardiac safety of such combinations.

7. CONCLUSIONS
==============

Trastuzumab has become a standard of care in the adjuvant and metastatic settings for patients with [her]{.smallcaps}2-positive breast cancer. The evolving data in the neoadjuvant setting suggest that the addition of trastuzumab to neoadjuvant systemic therapy significantly increases p[cr]{.smallcaps}, breast conservation rates, and event-free survival. A strategy of concurrent anthracyclines with trastuzumab appears promising, possibly further maximizing the efficacy of trastuzumab in high-risk patient populations. However, the cardiotoxicity risk (although relatively low so far) continues to be a concern. The present article provided panel suggestions based on available data about the use of trastuzumab preoperatively. The suggestions set out here will continue to evolve as data and experience with trastuzumab and other [her]{.smallcaps}2-targeted agents in trials of neoadjuvant systemic therapy emerge.

8. DATE OF PANEL SUGGESTIONS
============================

Panel suggestions were completed in June 2009.
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###### 

Key neoadjuvant trials of trastuzumab ([h]{.smallcaps})

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                                                                                    Treatment                                                                                                                                                        Patients\                                      Pathologic [cr]{.smallcaps}\         [dfs]{.smallcaps}\                                                                                                            
                                                                                                                                                                                                                                                                                                (*n*)                                          \[% (95% [ci]{.smallcaps})\]         \[% (95% [ci]{.smallcaps})\]                                                                                                  
  ---------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- ------------------------------------ ----------------------------------------------------------------- ----------------------------------------------------------- -----------------------------------------------------------
  Buzdar *et al.,* 2005[@b3-co16-5-48]\                                                                                        [h]{.smallcaps} + ([p]{.smallcaps}→[fec]{.smallcaps}) vs. [p]{.smallcaps}→[fec]{.smallcaps}                                                                      42\                                            65.2 (43--84)                        26.3 (9--51)                                                      ---                                                         ---
   (MD Anderson trial)                                                                                                                                                                                                                                                                          (stage [ii]{.smallcaps}--[iiia]{.smallcaps})                                                                                                                                                                      

  [p]{.smallcaps}=0.016                                                                                                        ---                                                                                                                                                                                                                                                                                                                                                                                

  Buzdar *et al.,* 2007[@b33-co16-5-48],[a](#tfn1-co16-5-48){ref-type="table-fn"}\                                                                                                                                                                                                              64                                             60.0 (44.3--74.3)                    26.3 (9--51)                                                      100 (85.2--100)[b](#tfn2-co16-5-48){ref-type="table-fn"}    85.3 (67.6--100)[b](#tfn2-co16-5-48){ref-type="table-fn"}
   (MD Anderson trial update)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                    100 (92--100)[c](#tfn3-co16-5-48){ref-type="table-fn"}            94.7 (85.2--100)[c](#tfn3-co16-5-48){ref-type="table-fn"}   

                                                                                                                                                                                                                                                                                                                                               [p]{.smallcaps} value not reported   [p]{.smallcaps}= 0.041[b](#tfn2-co16-5-48){ref-type="table-fn"}                                                               

  Gianni *et al.,* 2008[@b34-co16-5-48],[d](#tfn4-co16-5-48){ref-type="table-fn"},[e](#tfn5-co16-5-48){ref-type="table-fn"}\   [h]{.smallcaps} + ([ap]{.smallcaps}→[p]{.smallcaps}→[cmf]{.smallcaps}) →surgery→[h]{.smallcaps} vs. [ap]{.smallcaps}→[p]{.smallcaps}→[cmf]{.smallcaps}→surgery   227                                            43                                   23                                                                70.1[f](#tfn6-co16-5-48){ref-type="table-fn"}               53.3[f](#tfn6-co16-5-48){ref-type="table-fn"}
   [noah]{.smallcaps} trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                               [p]{.smallcaps}=0.002                                                                                                                                            [p]{.smallcaps}=0.006\                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                [hr]{.smallcaps}: 0.56                                                                                                                                                                                            

  Baselga *et al.,* 2007[@b35-co16-5-48]\                                                                                                                                                                                                                                                       61                                             55                                   19                                                                ---                                                         ---
   \[[noah]{.smallcaps} trial ([her]{.smallcaps}2+ [ibc]{.smallcaps})\]                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                [p]{.smallcaps}=0.004                          ---                                                                                                                                                                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Combined values, includes additional patients.

3-Year follow-up, does not include additional patients (*n*= 42).

1-Year follow-up, including additional patients.

Overall survival data not yet mature. Preliminary results show 17 events in the [h]{.smallcaps} arm and 22 events in the non-[h]{.smallcaps} arm. There is a positive trend for the [h]{.smallcaps} arm at a median follow-up of 3 years: [p]{.smallcaps} = 0.18; hazard ratio: 0.65.

3-Year median follow-up.

Presented as event-free survival, defined by either progression on therapy or relapse after surgery or death from any cause.

[cr]{.smallcaps}=complete response; [ci]{.smallcaps}= confidence interval; [dfs]{.smallcaps}= disease-free survival; [p]{.smallcaps}= paclitaxel; [fec]{.smallcaps}= 5-fluorouracil, epirubicin, cyclophosphamide; [ap]{.smallcaps}= doxorubicin, paclitaxel; [cmf]{.smallcaps}= cyclophosphamide, methotrexate, 5-fluorouracil; [hr]{.smallcaps}= hazard ratio; [ibc]{.smallcaps}= inflammatory breast cancer.

###### 

Future studies with [her]{.smallcaps}2--targeted therapy in the neoadjuvant setting

  Trial name (ClinicalTrials.gov [id]{.smallcaps})   Type                      Treatment                                                                                                                                                                                                                  Expected accrual   Estimated completion date
  -------------------------------------------------- ------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ---------------------------
  [acosog]{.smallcaps}-Z1041(NCT00513292)            Phase [iii]{.smallcaps}   [fec]{.smallcaps}~75~→[th]{.smallcaps} vs. [th]{.smallcaps}→[fec]{.smallcaps}~75~ + [h]{.smallcaps}                                                                                                                        270                June 2008
  EGF106988 (NCT00429299)                            Phase [ii]{.smallcaps}    Chemotherapy + [l]{.smallcaps} vs. chemotherapy + [h]{.smallcaps} vs. chemotherapy + [lh]{.smallcaps}                                                                                                                      120                June 2009
  03--311 (NCT00148668)                              Phase [ii]{.smallcaps}    [h]{.smallcaps} + vinorelbine vs. [dc]{.smallcaps}b[h]{.smallcaps}                                                                                                                                                         81                 December 2009
  Neo [altto]{.smallcaps} (NCT00553358)              Phase [iii]{.smallcaps}   [lh]{.smallcaps}→[lht]{.smallcaps} vs. [l]{.smallcaps}→[lt]{.smallcaps} vs. [h]{.smallcaps}→[ht]{.smallcaps}                                                                                                               450                April 2010
  [calgb]{.smallcaps}-40601 (NCT00770809)            Phase [iii]{.smallcaps}   [h]{.smallcaps} + [t]{.smallcaps} + [l]{.smallcaps} vs. [h]{.smallcaps} + [t]{.smallcaps} vs. [t]{.smallcaps} + [l]{.smallcaps}                                                                                            400                June 2010
  [nsabp]{.smallcaps} B-41 (NCT00486668)             Phase [iii]{.smallcaps}   [ac]{.smallcaps}→[th]{.smallcaps} vs. [ac]{.smallcaps}→[tl]{.smallcaps} vs. [ac]{.smallcaps}→[thl]{.smallcaps}                                                                                                             522                July 2010
  GSK-LAP107087 (NCT00499681)                        Phase [ii]{.smallcaps}    [l]{.smallcaps} + letrozole vs. placebo + letrozole                                                                                                                                                                        36                 July 2010
  1200.44 (NCT00826267)                              Phase [ii]{.smallcaps}    [bibw]{.smallcaps} 2992 vs. [l]{.smallcaps} vs. [h]{.smallcaps}                                                                                                                                                            120                December 2010
  [gbg]{.smallcaps} 44 (NCT00567554)                 Phase [iii]{.smallcaps}   [ec]{.smallcaps}→[d]{.smallcaps} vs. [ec]{.smallcaps}→[d]{.smallcaps} + [b]{.smallcaps} vs. [t]{.smallcaps} vs. [t]{.smallcaps} + everolimus vs. [ec]{.smallcaps}→[dh]{.smallcaps} vs. [ec]{.smallcaps}→[dl]{.smallcaps}   2547               December 2010
  [geicam]{.smallcaps}/2006-14 (NCT00841828)         Phase [ii]{.smallcaps}    [ec]{.smallcaps}→[d]{.smallcaps} + [l]{.smallcaps} vs. [ec]{.smallcaps}→[d]{.smallcaps} + [h]{.smallcaps}                                                                                                                  102                December 2011
  EU-20851 (NCT00674414)                             Phase [ii]{.smallcaps}    [h]{.smallcaps} vs. [h]{.smallcaps} + everolimus                                                                                                                                                                           120                April 2014
  NeoSphere (NCT00545688)                            Phase [ii]{.smallcaps}    [h]{.smallcaps} + [d]{.smallcaps} vs. [h]{.smallcaps} + [p]{.smallcaps} + [d]{.smallcaps} vs. [h]{.smallcaps} + [p]{.smallcaps} vs. [p]{.smallcaps} + [d]{.smallcaps}                                                      400                August 2014
  H-20464 (NCT00548184)                              Phase [ii]{.smallcaps}    [hl]{.smallcaps} vs. [hl]{.smallcaps} + endocrine therapy                                                                                                                                                                  64                 January 2015
  LPT109096 (NCT00524303)                            Phase [ii]{.smallcaps}    [fec]{.smallcaps}~75~→[th]{.smallcaps} vs. [fec]{.smallcaps}~75~→[thl]{.smallcaps}                                                                                                                                         99                 Not available

[f]{.smallcaps}= 5-fluorouracil; [e]{.smallcaps}= epirubicin; [c]{.smallcaps}= cyclophosphamide; [t]{.smallcaps}= paclitaxel; [h]{.smallcaps}= trastuzumab; [l]{.smallcaps}= lapatinib; [d]{.smallcaps}= docetaxel; [c]{.smallcaps}b= carboplatin; [a]{.smallcaps}= doxorubicin; [b]{.smallcaps}= bevacizumab; [p]{.smallcaps}= pertuzumab.
